3-fluorophenmetrazine (3-fpm) | Buy 3-fluorophenmetrazine online | How to Buy 3-fluorophenmetrazine (3-fpm). +(402) 819-6142
It is a stimulant that structurally and pharmacologically similar to phenmetrazine, a once-popular stimulant substance used for weight loss. It works by increasing the levels of serotonin, dopamine, and norepinephrine in the brain. It first appeared on the market in 2015 and immediately became popular among buyers. The stimulating effects of the drug are similar to amphetamine, but FPM provokes less nervousness and insomnia, which makes it suitable as a training tool or performance enhancer.
It is known that the supplement is well tolerated by the body and does not cause side effects when taken correctly and follow all precautions.
EFFECTS FROM 3-FPM:
- Stimulation – this substance is moderately energetic and stimulating but lighter than amphetamine or cocaine. In this way, it encourages physical activity, household chores, or repetitive tasks necessary for everyday life.
- Increased focus – there will be an opportunity to focus better on a specific case, and therefore better results.
- Increased motivation – the desire to play sports, improve your activity will increase, and hence your performance.
- Euphoria and mood lift – there is nothing to add here, a great state that motivates to new achievements.
- Increased sociability – pleasant well-being and a favorable atmosphere for communication are always the desired effects.
- Acceleration of thoughts – mental activity and concentration increase.
ADMINISTRATION & DOSAGE
It lasts from 5 to 8 hours and begins to work in 20-30 minutes if taken orally.
- Light dose: 10-25 mg
- Common: 25-50 mg
- Strong: 50-70 mg
If taken intranasally, it lasts from 3 to 6 hours and begins working in 5 minutes. Intranasal use causes a very painful burning sensation.
- Light dose: 10-20 mg
- Common: 20-35 mg
- Strong: 35-50 mg
It is recommended that you start with light doses to see how your body responds to the drug, and then consider increasing it.
It should be noted that it is not recommended to combine it with other substances; it can lead to unpleasant and negative consequences, even life-threatening.
SIDE EFFECTS:
In general, this drug does not provoke severe adverse effects, mainly if used in small quantities. It is also not recommended to combine it with other medications to avoid possible risks. If you follow all the instructions and the correct dosage, then no side effects should occur. In rare cases you may experience:
- Appetite suppression
- Sweating
- Anxiety
- Aggression
- Insomnia
- Increased blood pressure
- Increased heart rate
- Vasoconstriction
The drug is not very addictive, and you need to be careful with overdose. In this case, the following may occur:
- Agitation
- Temporary psychosis
- Seizures
Though illegal in the UK, in
many countries novel psychoactive substances are quasi-legal synthetic
compounds that are widely available online under the guise of researchchemicals.
These substances are
relatively cheap and are often undetectable in standard drug screens. Nearly
200 such compounds are introduced yearly, and little is usually known about
their metabolism or physiological effects.
Consequently, managing patients in overdose
situations on largely unknown substances usually involves supportive care,
however anticipating and managing atypical side effects are challenging in the
absence of knowledge of these compounds.
In this report, we discuss our encounter with
a 33-year-old unconscious man presenting with coingestion of a novel stimulant
3-fluorophenmetrazine with a rarely used benzodiazepine etizolam. This patient
developed seizure-like activity and delayed widespread T-wave inversions, bothof which ultimately resolved without sequelae.
‘Legal highs’ or ‘new/novel psychoactive substances’ sold as research chemicals have a grey legal status in most countries, particularly in North America. Disguised with the label ‘Not for human consumption’, they are able to evade the regulatory processes in mostcountries.
These synthetic compounds have increasing popularity due to their accessibility, low cost, psychoactive effects and inability to be detected by screening drug tests like immunoassays.
Up to 200 of these substances are designed
every year, with the majority first making appearances in Europe. Given
attempts by chemists to circumvent drug enforcement laws through slight
alteration of parent compounds which are already illegal, in 2016 the UK banned
all novel psychoactive substances.
Nevertheless worldwide, these
drugs are easily obtainable over the internet and present significant challenges
to patient management in emergency and critical care settings.
Typically, most patients who
overdose on these substances appear in the emergency room either obtunded orunconscious.
The approach to any
unconscious patient must first involve immediate stabilisation, and once
addressed, consider lethal and easily reversible causes that could kill the
patient in the next few minutes, such as hypoglycaemia, overdoses and intracranial
herniation.
The patient’s history,
usually from paramedics, along with a thorough primary survey and a few
ancillary laboratory tests, should rule out most immediately life-threatening
differential diagnoses and help initiate definitive treatment.
In our patient described below, after
definitive management of his airway and finding no other immediate concerns
from the primary survey, the history from the paramedics of finding the
3-fluorophenmetrazine (3-FPM) and etizolam drug packages supported drug
overdose as the cause of the patient’s symptoms.
This case of drug overdosing
on novel, cheap and easily obtainable psychoactive substances is unfortunately
an increasingly common emergency room presentation.
Patients should be reassessed
frequently and intensive care expert opinion should be sought early. If novel
substances are identified on history, a literature search for case reports may
help identify uncommon side effects for which early detection could
significantly improve patient outcomes.
Both labels stated ‘Not for
human consumption’. On examination, he was responsive only to painful stimuli
(Glasgow Coma Scale (GCS)=6, E1M4V1), with vitals respiratory rate 10/min,
temperature 36.6°C, SpO288%, pulse 64 beats/min, blood pressure 104/61 mm
Hg and blood glucose 5.1 mmol/L. Pupils were 5 mm bilateral and non-reactive.
His airway was clear with
equal air entry and regular palpable pulses. Oxygenation improved with a
non-rebreather mask at 12 L/min oxygen. Initial ECG showed sinus rhythm. On
emergency room arrival, he remained stable but still unresponsive.
Arterial blood gas revealed respiratory acidosis (pH 7.21 and PCO276.5 mm Hg). Naloxone 2 mg intravenously was administered with no effect. The patient was subsequently intubated with ketamine and succinylcholine.
A nasogastric tube was inserted, an arterial line
was established, and a propofol infusion was started.
Portable chest X-rays and CT
head revealed no acute abnormalities. Blood alcohol was negative. A rapid
7-drug urine drug screen was positive for benzodiazepines and indeterminate for
amphetamines. A more extensive 42-drug urine screen was negative for other
commonly abused drugs.
On collateral history, this
patient had no significant medical or surgical history other than anxiety
treated with occasional lorazepam, however his prescription had run out 2 weeks
prior. His known drug use history included distant cannabis use. Physical
examination was significant only for abrasions on the scalp and lower limbs
with no evidence of intravenous drug use.
After workup in the emergency department, the patient was admitted to intensive care for monitoring. Abnormal four-limb movements concerning for possible seizure activity were observed in the afternoon of his first day in the hospital despite propofol infusion.
This settled with lorazepam. He developed a fever of 38.9°C that same evening
and was pan-cultured and started on vancomycin and metronidazole. An extensive
workup revealed only positive sputum culture for Staphylococcus
aureus, and his antibiotics were stepped down to
cefazolin on the fourth day postadmission. By this time, no further abnormal
movements were observed, and his propofol infusion was weaned, and he was
extubated once awake.
On the fifth day after admission, he was
transferred to a regular hospital bed from the intensive care unit but was
noted to have new widespread T-wave inversions on ECG .He was however
asymptomatic. These improved prior to discharge on day 7 after having been
cleared by psychiatry. Arrangements were made to follow up with his family
doctor and for addictions counselling, but he declined both. Follow-up cardiac
stress testing 5 days after discharge was within normal limits.
3-FPM, also known as PAL-593,
first became available in 2014, and is a fluorinated version of phenmetrazine an
abused drug from the 1960s used as an appetite suppressant.3-FPM acts as a norepinephine dopamine
releasing agent and hence has stimulatory properties. To date, there are three
case reports on 3-FPM misuse.
The first is an observational
case series from Sweden with 19 patients with analytically confirmed acute
polyintoxication including 3-FPM.3 Unfortunately, no unique toxidrome was
confirmed.
Symptoms observed included
tachycardia, reduced level of consciousness, agitation, delirium, dilated
pupils, seizures, hypertension, respiratory depression and rhabdomyolysis.
Another report from the
UK involved a patient who used 3-FPM intravenously and required a period of
renal replacement therapy and bilateral lower limb amputation following
development of irreversible four-limb ischaemia. 3-FPM, in combination
with the synthetic opioid U-47700 and several designer benzodiazepines, was
found in the blood and urine of a 34-year-old man at autopsy.
GET IN TOUCH
Email:
steroidsplug41@gmail.com
Phone:
(402) 819-6142
Whatsapp usa:
+(402) 819-6142
Comments
Post a Comment